Vidofludimus
Modify Date: 2024-01-08 06:20:04
Vidofludimus structure
|
Common Name | Vidofludimus | ||
|---|---|---|---|---|
| CAS Number | 717824-30-1 | Molecular Weight | 355.360 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 567.5±50.0 °C at 760 mmHg | |
| Molecular Formula | C20H18FNO4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 297.0±30.1 °C | |
Use of VidofludimusVidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.IC50 value:Target: DHODH inhibitorin vitro: 4SC-101 is a potent inhibitor of human DHODH, inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes [2].in vivo: In vivo Vido treatment alone most effectively reduced macroscopic and histological pathology and the numbers of CD3+ T cells. In contrast, similarly reduced nuclear signal transducer and activator of transcription 3 (STAT3) binding and IL-17 levels were observed from animals treated with Vido alone and Vido + Uri. Vido improves TNBS-induced colonic inflammation by a unique dual mode of action [1]. Oral administration of 4SC-101 effectively improved both chronic DSS and acute TNBS colitis in mice. In these colitis models the overall efficacy profile of 4SC-101 was similar to that of dexamethasone [2]. |
| Name | 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.IC50 value:Target: DHODH inhibitorin vitro: 4SC-101 is a potent inhibitor of human DHODH, inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes [2].in vivo: In vivo Vido treatment alone most effectively reduced macroscopic and histological pathology and the numbers of CD3+ T cells. In contrast, similarly reduced nuclear signal transducer and activator of transcription 3 (STAT3) binding and IL-17 levels were observed from animals treated with Vido alone and Vido + Uri. Vido improves TNBS-induced colonic inflammation by a unique dual mode of action [1]. Oral administration of 4SC-101 effectively improved both chronic DSS and acute TNBS colitis in mice. In these colitis models the overall efficacy profile of 4SC-101 was similar to that of dexamethasone [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 567.5±50.0 °C at 760 mmHg |
| Molecular Formula | C20H18FNO4 |
| Molecular Weight | 355.360 |
| Flash Point | 297.0±30.1 °C |
| Exact Mass | 355.121979 |
| PSA | 79.12000 |
| LogP | 4.22 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.634 |
| Storage condition | -20℃ |
![3-FLUORO-3'-METHOXY[1,1'-BIPHENYL]-4-AMINE structure](https://image.chemsrc.com/caspic/144/867287-99-8.png)
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| 2-[(3-Fluoro-3'-methoxy-4-biphenylyl)carbamoyl]-1-cyclopentene-1-carboxylic acid |
| 4SC-101 |
| 2-(3-Fluoro-3'-methoxy-biphenyl-4-ylcarbamoyl)-cyclopent-1-ene-carboxylic acid |
| 1-Cyclopentene-1-carboxylic acid, 2-[[(3-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl)amino]carbonyl]- |
| 2-((3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)carbamoyl)cyclopent-1-enecarboxylic acid |
| Vidofludimus [INN] |
| 2-[(3-Fluoro-3'-methoxybiphenyl-4-yl)carbamoyl]cyclopent-1-ene-1-carboxylic acid |
| Vidofludimus |
| SC12267 |